We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
바이오 제약 회사인 Kiniksa Pharmaceuticals International, plc는 미국, 영국 및 전 세계적으로 의료 치료제를 개발하고 상용화합니다. 동사는 만성 자가염증성 심혈관 질환인 재발성 심낭염과 심장 사르코이드증 치료를 위한 인터루킨-1알파 및 1베타 사이토카인 트랩인 ARCALYST를 제공합니다. 또한 동사는 재발성 심낭염 치료를 위해 2/3상 임상 시험 중인 완전 인간 면역글로불린 G2 단일클론 항체인 KPL-387과 전임상 단계에 있는 Fc 변형 면역글로불린 G2 단일클론 항체인 KPL-116을 개발하고 있습니다. 동사의 이전 사명은 Kiniksa Pharmaceuticals, Ltd.였으며, 2024년 6월에 Kiniksa Pharmaceuticals International, plc로 사명을 변경했습니다. Kiniksa Pharmaceuticals International, plc는 2015년에 설립되었으며 영국 런던에 본사를 두고 있습니다.